Streetbeat News

XAIR

Beyond Air, Inc.

https://www.beyondair.net

Industry

Medical - Devices

Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

Open

0.46

Mkt cap

33M

Volume

400K

High

0.48

P/E Ratio

-0.33

52-wk high

2.36

Low

0.44

Div yield

N/A

52-wk low

0.30

Beyond Cancer, Ltd. has received approval from the Israeli Ministry of Health to conduct a Phase 1b clinical trial using Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in combination with anti-PD-1 therapy for solid tumors. The trial will start patient screening in early 2025 at four sites in Israel.

Portfolio Pulse from

December 03, 2024 | 9:30 pm

Beyond Air has received the CE Mark in Europe for its LungFit® PH System, which is used to treat newborns with hypoxic respiratory failure and pulmonary hypertension. This approval could enhance the company's market presence and revenue potential in Europe.

Portfolio Pulse from

December 02, 2024 | 12:45 pm

NeuroNOS has appointed Nobel Laureate Roger D. Kornberg to its Scientific Advisory Board. Kornberg will help accelerate the development of treatments for Autism Spectrum Disorder and other neurological disorders.

Portfolio Pulse from

November 26, 2024 | 12:45 pm

Beyond Air, Inc. (NASDAQ: XAIR) will participate in the Piper Sandler 36th Annual Healthcare Conference, with CEO Steve Lisi engaging in one-on-one meetings and a fireside chat. This participation could increase visibility and investor interest in the company, which focuses on medical devices and biopharmaceuticals utilizing Nitric Oxide.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

Beyond Air, Inc. (NASDAQ:XAIR) held its Q2 2025 earnings call on November 11, 2024, discussing financial results for the quarter ending September 30, 2024. Key participants included company executives and analysts from various firms.

Portfolio Pulse from

November 12, 2024 | 1:15 am

Beyond Air, Inc. (XAIR) reported a Q2 loss of $0.28 per share, which was better than the Zacks Consensus Estimate of a $0.30 loss. This is an improvement from the $0.51 loss per share a year ago.

Portfolio Pulse from

November 11, 2024 | 11:30 pm

Beyond Air reported a 17% revenue increase for Q2 2025, strengthened its balance sheet, and completed a $20.6 million private placement. The company retired $17.5 million in debt and secured an $11.5 million loan. A conference call is scheduled for November 11.

Portfolio Pulse from

November 11, 2024 | 9:30 pm

Several healthcare stocks experienced significant price movements during Friday's intraday session. Notable gainers included Athira Pharma, ChromaDex, and Theriva Biologics, while Lexicon Pharmaceuticals and Myriad Genetics were among the biggest losers.

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 4:36 pm

Several healthcare stocks experienced significant movements in Monday's pre-market session. Notable gainers include Evoke Pharma, Healthcare Triangle, and Monte Rosa Therapeutics, while Koninklijke Philips and Monopar Therapeutics were among the losers.

Portfolio Pulse from Benzinga Insights

October 28, 2024 | 12:07 pm

In Friday's after-market session, several healthcare stocks experienced significant price movements. Healthcare Triangle, Mira Pharmaceuticals, MEI Pharma, TuHURA Biosciences, P3 Health Partners, and OKYO Pharma saw notable gains, while Aclaris Therapeutics, Beyond Air, Qualigen Therapeutics, Nuwellis, Compass Pathways, and Helius Medical Tech experienced declines.

Portfolio Pulse from Benzinga Insights

October 25, 2024 | 8:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.